Italian

Sarcoma

Group

IItaliantalian

SSarcomaarcoma

GGrouproup

StartedJune 1997

StartedJune 1997

FormalizedOctober 2002Formalized

October 2002

www.italiansarcomagroup.org

68 Centers

• 14 National Institutes

• 14 Universities

• 34 Pubblic Hospitals

• 6 Private Hospitals

68 Centers

• 14 National Institutes

• 14 Universities

• 34 Pubblic Hospitals

• 6 Private Hospitals

Italian Sarcoma GroupItalian Sarcoma Group

210 members210 members

11

1 31

11

18

10 2

1

1 111

1 3

1

1

2 at november 2005at november 2005

11

1 1

1

2

5

1

1BELGIUM

1

1

2

11

11

1

6

1

• ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts Closed JCO 2005

• ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 pts Closed ASCO 2005

• ISG/OS I (localized disease) activated 4/2001, 237 pts

• EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 120 pts

• High risk (relapsed patients) activated 12/2002, 36 pts

• H.D. Samarium + PBSCR in multiple bone lesions activated 11/2005, 6 pts

• ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts Closed JCO 2005

• ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 pts Closed ASCO 2005

• ISG/OS I (localized disease) activated 4/2001, 237 pts

• EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 120 pts

• High risk (relapsed patients) activated 12/2002, 36 pts

• H.D. Samarium + PBSCR in multiple bone lesions activated 11/2005, 6 pts

Osteosarcoma ProtocolsOsteosarcoma ProtocolsItalian Sarcoma GroupItalian Sarcoma Group

• ISG/SSG III (standard risk)activated 6/99, 264 pts ASCO 2007

• ISG/SSG IV (high risk)activated 6/99, 82 pts ASCO 2005

• ISG/AIEOP (very high risk)activated 12/2002, 25 pts

Closed In press EJC 2006

• Relapsed Patientsactivated 12/2002, 32 pts ASCO 2007 ?

• ISG/SSG III (standard risk)activated 6/99, 264 pts ASCO 2007

• ISG/SSG IV (high risk)activated 6/99, 82 pts ASCO 2005

• ISG/AIEOP (very high risk)activated 12/2002, 25 pts

Closed In press EJC 2006

• Relapsed Patientsactivated 12/2002, 32 pts ASCO 2007 ?

Ewing’s Sarcoma ProtocolsEwing’s Sarcoma ProtocolsItalian Sarcoma GroupItalian Sarcoma Group

• ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk

localized disease) with Spanish Group (282 pts)

• ISG/STS 03/02 (neodjuvant IFO+RT in retroper. (30 pts)

• HD-IFX in continuous infusion (2nd-4th line) (32 pts)

• Gemcytabine in leiomyosarcomas (2nd-3rd line) (20 pts)

• Miniallogenic Transplant (advanced disease, responsive

patients) (6 pts)

• Phase 2 Trabectedin in myxoid liposarcoma

Other• Imatinib in advanced chordoma (50 pts) (ASCO 2007)

• ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk

localized disease) with Spanish Group (282 pts)

• ISG/STS 03/02 (neodjuvant IFO+RT in retroper. (30 pts)

• HD-IFX in continuous infusion (2nd-4th line) (32 pts)

• Gemcytabine in leiomyosarcomas (2nd-3rd line) (20 pts)

• Miniallogenic Transplant (advanced disease, responsive

patients) (6 pts)

• Phase 2 Trabectedin in myxoid liposarcoma

Other• Imatinib in advanced chordoma (50 pts) (ASCO 2007)

Adult soft tissue sarcomas - ProtocolsAdult soft tissue sarcomas - ProtocolsItalian Sarcoma GroupItalian Sarcoma Group

• GIOTTO (observational, 2004-2005, in collaboration with

Novartis) (790 pts) Closed

• REGISTER (retrospective, histhological) (470 pts)

• 62024 (adjuvant Imatinib), intergroup with EORTC

(49/418 pts)

• Institutions from the ISG are participating in the

following studies on new agents in GIST:• Sunitinib (international)

• PTK787 (international)

• Nilotinib (international)

• GIOTTO (observational, 2004-2005, in collaboration with

Novartis) (790 pts) Closed

• REGISTER (retrospective, histhological) (470 pts)

• 62024 (adjuvant Imatinib), intergroup with EORTC

(49/418 pts)

• Institutions from the ISG are participating in the

following studies on new agents in GIST:• Sunitinib (international)

• PTK787 (international)

• Nilotinib (international)

GIST ProtocolsGIST Protocols

In preparation

• Osteosarcoma: localized disease

• Ewing’s sarcoma: localized disease

• Soft tissue sarcomas: high risk, localized

• Surgery in GIST after Imatinib (intergroup)

• Imatinib in localized chordoma

• Imatinib in Chs and fibromatosis